Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Breedveld, F C
Right arrow Articles by Van der Lubbe, P A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Breedveld, F C
Right arrow Articles by Van der Lubbe, P A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 51:493-502 (1995)
© 1995 The British Council

research-article

Monoclonal antibody therapy of inflammatory rheumatic diseases

F C Breedveld and P A Van der Lubbe

Department of Rheumatology, University Hospital Leiden, The Netherlands

Abstract

The recognition that certain monoclonal antibodies have immunosuppressive properties led to the therapeutic application in autoimmune rheumatic diseases, rheumatoid arthritis in particular. The therapeutic potential of monoclonal antibodies directed against cell surface antigens mainly present on T-cells has been suggested by open trials in rheumatoid arthritis but the results of controlled studies are disappointing. Open intervention studies with monoclonal antibodies directed at other antigens relevant for the rheumatoid inflammation such as the intercellular adhesion molecule ICAM-1 or the cytokines IL-6 and TNF{alpha} provided encouraging clinical improvements. The impressive potential of anti-TNF{alpha} which was already illustrated by the immediate suppression of the acute phase response in open studies could be confirmed by a recently completed controlled trial. The present overview summarizes the available information on the results of these treatment modalities and discusses the possibilities of monoclonal antibodies as a long term treatment for rheumatic diseases.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
A F Wahl and P M Wallace
Oncostatin M in the anti-inflammatory response
Ann Rheum Dis, November 1, 2001; 60(90003): iii75 - 80.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. Hamann and U. Syrbe
T-cell trafficking into sites of inflammation
Rheumatology, July 1, 2000; 39(7): 696 - 699.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
P. M. Wallace, J. F. MacMaster, K. A. Rouleau, T. J. Brown, J. K. Loy, K. L. Donaldson, and A. F. Wahl
Regulation of Inflammatory Responses by Oncostatin M
J. Immunol., May 1, 1999; 162(9): 5547 - 5555.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.